Sagimet Biosciences Inc (SGMT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.94+0.18%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SGMT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenues | — | — | — | 2.0 | — | — |
| Operating Expenses & Income | ||||||
| R&D Expenses | 35.0 | 39.1 | 38.4 | 19.8 | 24.9 | — |
| Operating Income | (52.6) | (56.9) | (54.5) | (30.7) | (31.1) | — |
| Net Income | ||||||
| Net Income | (47.1) | (51.0) | (45.6) | (27.9) | (30.5) | — |
| Per Share | ||||||
| Basic EPS | (0.89) | (1.58) | (1.45) | (2.66) | (165.20) | — |
| Diluted EPS | (0.89) | (1.58) | (1.45) | (2.66) | (165.20) | — |
| Basic Weighted Avg Shares | 53.1 | 32.3 | 31.4 | 10.5 | 0.2 | — |
| Diluted Weighted Avg Shares | 53.1 | 32.3 | 31.4 | 10.5 | 0.2 | — |
| Supplemental | ||||||
| EBIT | (52.6) | (56.9) | (54.5) | (30.7) | (31.1) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.